The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
PaFLO: Pazopanib with 5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line treatment in advanced gastric cancer: A randomized phase II study of theĀ  Arbeitsgemeinschaft internistische Onkologie (AIO).
Kirstin Breithaupt
No relevant relationships to disclose
Dmitry Bichev
No relevant relationships to disclose
Mario Lorenz
No relevant relationships to disclose
Daniela Bohnen
No relevant relationships to disclose
Yasemin Dogan
No relevant relationships to disclose
Peter Schlattmann
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose
Markus Hermann Moehler
No relevant relationships to disclose
Peter C. Thuss-Patience
Research Funding - GlaxoSmithKline